A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine

PLoS Pathogens

Volumn 13, Issue 10, 2017, Pages

  Wu, Nicholas C ^a   Zost, Seth J ^b   Thompson, Andrew J ^a   Oyen, David ^a   Nycholat, Corwin M ^a   McBride, Ryan ^a   Paulson, James C ^a   Hensley, Scott E ^b   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN; GLYCOPROTEIN; HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIGEN;

AMINO ACID SUBSTITUTION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BINDING ASSAY; BINDING SITE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HYDROGEN BOND; INFLUENZA A VIRUS (H3N2); INTERFEROMETRY; MOLECULAR DYNAMICS; NONHUMAN; POULTRY EGG; PREVALENCE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PUBLIC HEALTH PROBLEM; RECEPTOR BINDING; SEASONAL INFLUENZA; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; CHEMISTRY; IMMUNOLOGY; INFLUENZA;

AMINO ACID SUBSTITUTION; ANTIGENS, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 85033229591     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006682     Document Type: Article

References (58)

1. Wiley DC, Wilson IA, Skehel JJ, Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289(5796):373–8. 6162101.
2. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A. 1984;81(6):1779–83. 6584912; PubMed Central PMCID: PMCPMC345004.
3. Wiley DC, Skehel JJ, The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365–94. doi: 10.1146/annurev.bi.56.070187.002053 3304138.
4. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, et al. High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution. Sci Rep. 2014;4:4942. doi: 10.1038/srep04942 24820965; PubMed Central PMCID: PMCPMC4018626.
5. Thyagarajan B, Bloom JD, The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. eLife. 2014;3:e03300. doi: 10.7554/eLife.03300 25006036; PubMed Central PMCID: PMCPMC4109307.
6. Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M, et al. Vaccines through centuries: major cornerstones of global health. Front Public Health. 2015;3:269. doi: 10.3389/fpubh.2015.00269 26636066; PubMed Central PMCID: PMCPMC4659912.
7. Osterholm MT, Kelley NS, Sommer A, Belongia EA, Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44. doi: 10.1016/S1473-3099(11)70295-X 22032844.
8. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51. doi: 10.1016/S1473-3099(16)00129-8 27061888.
9. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153. doi: 10.1371/journal.pone.0092153 24667168; PubMed Central PMCID: PMCPMC3965421.
10. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4). 25655053.
11. Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol. 1997;71(4):3357–62. 9060710; PubMed Central PMCID: PMCPMC191479.
12. Sriwilaijaroen N, Kondo S, Yagi H, Wilairat P, Hiramatsu H, Ito M, et al. Analysis of N-glycans in embryonated chicken egg chorioallantoic and amniotic cells responsible for binding and adaptation of human and avian influenza viruses. Glycoconj J. 2009;26(4):433–43. doi: 10.1007/s10719-008-9193-x 18853253.
13. Rogers GN, Daniels RS, Skehel JJ, Wiley DC, Wang XF, Higa HH, et al. Host-mediated selection of influenza virus receptor variants. Sialic acid-α2,6Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-α2,3Gal-specific wild type in ovo. J Biol Chem. 1985;260(12):7362–7. 3997874.
14. Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, Robertson JS, et al. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'-sialyl(N-acetyllactosamine). Virology. 1997;232(2):345–50. doi: 10.1006/viro.1997.8572 9191848.
15. Gambaryan AS, Karasin AI, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV, et al. Receptor-binding properties of swine influenza viruses isolated and propagated in MDCK cells. Virus Res. 2005;114(1–2):15–22. doi: 10.1016/j.virusres.2005.05.005 15996787.
16. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM, The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol. 1993;74((Pt 10)):2047–51. doi: 10.1099/0022-1317-74-10-2047 8409929.
17. Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology. 1987;160(1):31–7. 3629978.
18. Kodihalli S, Justewicz DM, Gubareva LV, Webster RG, Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol. 1995;69(8):4888–97. 7609057; PubMed Central PMCID: PMCPMC189303.
19. Chen Z, Zhou H, Jin H, The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine. 2010;28(24):4079–85. doi: 10.1016/j.vaccine.2010.03.078 20399830.
20. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012;7(7):e41895. doi: 10.1371/journal.pone.0041895 22848649; PubMed Central PMCID: PMCPMC3405050.
21. Parker L, Wharton SA, Martin SR, Cross K, Lin Y, Liu Y, et al. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virol. 2016;97(6):1333–44. doi: 10.1099/jgv.0.000457 26974849.
22. Raymond DD, Stewart SM, Lee J, Ferdman J, Bajic G, Do KT, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med. 2016;22(12):1465–9. doi: 10.1038/nm.4223 27820604.
23. Hartgroves LC, Koudstaal W, McLeod C, Moncorge O, Thompson CI, Ellis J, et al. Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine. 2010;28(17):2973–9. doi: 10.1016/j.vaccine.2010.02.012 20188682.
24. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?J Virol. 2010;84(13):6769–81. doi: 10.1128/JVI.00458-10 20410266; PubMed Central PMCID: PMCPMC2903250.
25. Stevens J, Chen LM, Carney PJ, Garten R, Foust A, Le J, et al. Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol. 2010;84(16):8287–99. doi: 10.1128/JVI.00058-10 20519409; PubMed Central PMCID: PMCPMC2916524.
26. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature. 2012;489(7417):526–32. doi: 10.1038/nature11414 22982990; PubMed Central PMCID: PMCPMC3538848.
27. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE, Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep. 2015;12(1):1–6. doi: 10.1016/j.celrep.2015.06.005 26119736; PubMed Central PMCID: PMCPMC4487778.
28. Shi Y, Wu Y, Zhang W, Qi J, Gao GF, Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Microbiol. 2014;12(12):822–31. doi: 10.1038/nrmicro3362 25383601.
29. Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, et al. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature. 2013;497(7449):392–6. doi: 10.1038/nature12144 23615615.
30. Sabesan S, Bock K, Paulson JC, Conformational analysis of sialyloligosaccharides. Carbohydr Res. 1991;218:27–54. 1802388.
31. Asensio JL, Arda A, Canada FJ, Jimenez-Barbero J, Carbohydrate-aromatic interactions. Acc Chem Res. 2013;46(4):946–54. doi: 10.1021/ar300024d 22704792.
32. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A. 2012;109(52):21474–9. doi: 10.1073/pnas.1218841110 23236176; PubMed Central PMCID: PMCPMC3535595.
33. Xu R, McBride R, Paulson JC, Basler CF, Wilson IA, Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010;84(4):1715–21. doi: 10.1128/JVI.02162-09 20007271; PubMed Central PMCID: PMCPMC2812380.
34. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol. 2006;355(5):1143–55. doi: 10.1016/j.jmb.2005.11.002 16343533.
35. Peng W, de Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, et al. Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for Increased avidity. Cell Host Microbe. 2017;21:1–12.
36. Meisner J, Szretter KJ, Bradley KC, Langley WA, Li ZN, Lee BJ, et al. Infectivity studies of influenza virus hemagglutinin receptor binding site mutants in mice. J Virol. 2008;82(10):5079–83. doi: 10.1128/JVI.01958-07 18353965; PubMed Central PMCID: PMCPMC2346734.
37. Martin J, Wharton SA, Lin YP, Takemoto DK, Skehel JJ, Wiley DC, et al. Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology. 1998;241(1):101–11. 9454721.
38. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420(6916):678–82. doi: 10.1038/nature01188 12478295.
39. MacRaild CA, Zachrdla M, Andrew D, Krishnarjuna B, Novacek J, Zidek L, et al. Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2. PLoS One. 2015;10(3):e0119899. doi: 10.1371/journal.pone.0119899 25742002; PubMed Central PMCID: PMCPMC4351039.
40. Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, et al. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A. 2016;113(45):12768–73. doi: 10.1073/pnas.1609780113 27791120; PubMed Central PMCID: PMCPMC5111675.
41. Milian E, Kamen AA, Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015;2015:504831. doi: 10.1155/2015/504831 25815321; PubMed Central PMCID: PMCPMC4359798.
42. Katoh K, Standley DM, MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30(4):772–80. doi: 10.1093/molbev/mst010 23329690; PubMed Central PMCID: PMCPMC3603318.
43. McWhite CD, Meyer AG, Wilke CO, Sequence amplification via cell passaging creates spurious signals of positive adaptation in influenza virus H3N2 hemagglutinin. Virus Evol. 2016;2(2):vew026. doi: 10.1093/ve/vew026 27713835; PubMed Central PMCID: PMCPMC5049878.
44. Otwinowski Z, Minor W, Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26. doi: 10.1016/s0076-6879(97)76066-x
45. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–74. doi: 10.1107/S0021889807021206 19461840; PubMed Central PMCID: PMCPMC2483472.
46. Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, et al. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun. 2014;5:3614. doi: 10.1038/ncomms4614 24717798; PubMed Central PMCID: PMCPMC4358779.
47. Emsley P, Lohkamp B, Scott WG, Cowtan K, Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. doi: 10.1107/S0907444910007493 20383002; PubMed Central PMCID: PMCPMC2852313.
48. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):355–67. doi: 10.1107/S0907444911001314 21460454; PubMed Central PMCID: PMCPMC3069751.
49. Chen VB, Arendall WB, 3rdHeadd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21. doi: 10.1107/S0907444909042073 20057044; PubMed Central PMCID: PMCPMC2803126.
50. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C, ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11(8):3696–713. doi: 10.1021/acs.jctc.5b00255 26574453; PubMed Central PMCID: PMCPMC4821407.
51. Kirschner KN, Yongye AB, Tschampel SM, Gonzalez-Outeirino J, Daniels CR, Foley BL, et al. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem. 2008;29(4):622–55. doi: 10.1002/jcc.20820 17849372; PubMed Central PMCID: PMCPMC4423547.
52. Horn HW, Swope WC, Pitera JW, Madura JD, Dick TJ, Hura GL, et al. Development of an improved four-site water model for biomolecular simulations: TIP4P-Ew. J Chem Phys. 2004;120(20):9665–78. doi: 10.1063/1.1683075 15267980.
53. Case DA, Betz RM, Cerutti DS, Cheatham I, T. E., Darden TA, Duke RE, et al. AMBER 2016. University of California, San Francisco.
54. Hopkins CW, Le Grand S, Walker RC, Roitberg AE, Long-time-step molecular dynamics through hydrogen mass repartitioning. J Chem Theory Comput. 2015;11(4):1864–74. doi: 10.1021/ct5010406 26574392.
55. Roe DR, Cheatham TE, 3rdPTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9(7):3084–95. doi: 10.1021/ct400341p 26583988.
56. Yuan Z, Zhao J, Wang ZX, Flexibility analysis of enzyme active sites by crystallographic temperature factors. Protein Eng. 2003;16(2):109–14. 12676979.
57. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999;96(16):9345–50. 10430945; PubMed Central PMCID: PMCPMC17785.
58. Ha Y, Stevens DJ, Skehel JJ, Wiley DC, H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J. 2002;21(5):865–75. doi: 10.1093/emboj/21.5.865 11867515; PubMed Central PMCID: PMCPMC125880.